|
|
市场分析报告
|
Global Market Report of Ralfinamide (CAS 133865-88-0) December 2024
CAS 133865-88-0 Ralfinamide Chemical Report & Database ... listed. The substance covered (Ralfinamide) are classified by the ... & Database definitions: Name: Ralfinamide: Ralfinamide; (S)-2-[[4-[(2-Fluorobenzyl)oxy]benzyl]amino] ... Chemical or Reaction Intermediate The Ralfinamide Report & Database gives Market ...
Newron Pharmaceuticals S.p.A. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... for the treatment of Parkinsons disease; Ralfinamide for treating neuropathic low back ...
Chronic Neuropathic Pain (CNP) - Pipeline Insight, 2019 This report can be delivered to the clients within 24 Hours "Chronic Neuropathic Pain (CNP) - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture ...
Neuropathic Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major neuropathic pain markets reached a value of US$ 5.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 8.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.7% during 2024-2034. The neuropathic pain market has been ...
Newron Pharmaceuticals SpA (NWRN) - Financial and Strategic SWOT Analysis Review ... . Newron’s other products in pipeline include ralfinamide for neuropathic pain; sarizotan for ...
|
|
|
|